semaglutide for non obese patients guidelines based on BMI may exclude at-risk Indians Global semaglutide eligibility criteria based on BMI may not reflect Indian risk patterns, potentially excluding high-risk who develop cardiovascular disease at lower nejm Semaglutide, a glucagon-like peptide-1

For people who experience allergy symptoms while taking semaglutide, it is important to track when the symptoms started and how severe they are

When the gut microbiome shifts during perimenopause, this process becomes less efficient, contributing to the symptoms many women experience

GLP-1 Starter Kit Just got your prescription

How much weight loss can I expect from metformin plus GLP-1 therapy

Nauck MA, Petrie JR, Sesti G et al (2016) A phase 2, randomized, dose-finding study of the novel once-weekly human GLP-1 analog, semaglutide, compared with placebo and open-label liraglutide in patients with type 2 diabetes